Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Diabetes Res Clin Pract ; 135: 93-101, 2018 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-29154913

RESUMO

The World Health Organisation recommends exclusive breastfeeding for the first six months of life (Australian institute of health and welfare, 2011). Breastfeeding confers many short- and long-term benefits for infants and mothers, including reduced childhood obesity and lower maternal body weight (Infant feeding survey, 2010; CDC National immunization surveys, 2012 and 2013; Sorkio et al., 2010; Hummel et al., 2014; Finkelstein et al., 2013). Exclusive breastfeeding is also recommended in women with type 1 diabetes mellitus (T1DM), for at least four months (Nucci et al., 2017). However, the impact of breastfeeding on mothers with T1DM, and, conversely, the impact of maternal T1DM on breastfeeding, is not clear. This review summarizes current knowledge regarding the epidemiology and physiology of breastfeeding in women with T1DM. In particular, it highlights the relationship between breastfeeding and glycaemia. Potential areas for future research are also identified.


Assuntos
Aleitamento Materno/métodos , Diabetes Mellitus Tipo 1/fisiopatologia , Feminino , Humanos , Lactente , Recém-Nascido
2.
J Clin Endocrinol Metab ; 100(5): 2024-9, 2015 May.
Artigo em Inglês | MEDLINE | ID: mdl-25719931

RESUMO

CONTEXT: Hypercalcemia is a common complication of cancer with PTHrP an important mediator. Literature on the underlying causes of PTHrP-mediated hypercalcemia, in both malignant and benign conditions, is limited to small case series and case reports. OBJECTIVE: The purpose of this study was to systematically identify a large series of cases of PTHrP-mediated hypercalcemia and to document differences in demographics and the clinical course between malignant and benign etiologies. DESIGN, SETTING, AND PATIENTS: This was a hospital-based, retrospective case series that identified subjects from 1999 to 2010 from the public hospital system in Queensland, Australia. Included subjects were 18 years and older and had persistent hypercalcemia with simultaneously elevated PTHrP. RESULTS: A total of 138 cases were identified. Solid organ malignancies made up 82.6% (n = 114) of cases, with squamous cell carcinoma (28.2% of total) and adenocarcinomas (27.5%) almost equally as common. Hematological malignancy and benign conditions made up 8.7% (n = 12) each. Squamous cell carcinoma of the lung was the single most commonly identified etiology (10.9%). Causes not previously identified included myxoid sarcoma, plasma cell leukemia, duodenal adenocarcinoma, metastatic Merkel cell carcinoma, and epithelioid hemangioendothelioma. Median survival was different among the groups (52 days [interquartile range, 21-132 days] for solid organ malignancy, 362 days [18-652 days] for hematological malignancy, and 906 days [16 days to undefined] for the apparently benign group; P < .0001). There were no differences in PTHrP among the groups. Although the mean corrected calcium level was lower in the benign group (3.03 mmol/L [2.80-3.29 mmol/L]) compared with that in the solid organ (3.11 mmol/L [2.89-3.46 mmol/L]) and hematological malignancy groups (3.60 mmol/L [3.01-3.79 mmol/L]) groups (P = .046), it was not a useful discriminator of etiology. CONCLUSION: PTHrP-mediated hypercalcemia is most frequently caused by solid organ malignancy, and it portends a poor prognosis. Although the solid organ malignancy group had the shortest survival, the hematological malignancy and apparently benign causes groups still had relatively short overall survival.


Assuntos
Hipercalcemia/etiologia , Neoplasias/complicações , Proteína Relacionada ao Hormônio Paratireóideo/sangue , Idoso , Cálcio/sangue , Feminino , Humanos , Hipercalcemia/sangue , Hipercalcemia/mortalidade , Masculino , Pessoa de Meia-Idade , Neoplasias/sangue , Neoplasias/mortalidade , Prognóstico , Estudos Retrospectivos , Taxa de Sobrevida
3.
Diabetes Care ; 37(2): 364-71, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24130361

RESUMO

OBJECTIVE: We aimed to 1) describe the peripartum management of type 1 diabetes at an Australian teaching hospital and 2) discuss factors influencing the apparent transient insulin independence postpartum. RESEARCH DESIGN AND METHODS: We conducted a retrospective review of women with type 1 diabetes delivering singleton pregnancies from 2005 to 2010. Information was collected regarding demographics, medical history, peripartum management and outcome, and breast-feeding. To detect a difference in time to first postpartum blood glucose level (BGL) >8 mmol/L between women with an early (<4 h) and late (>12 h) requirement for insulin postpartum, with a power of 80% and a type 1 error of 0.05, at least 24 patients were required. RESULTS: An intravenous insulin infusion was commenced in almost 95% of women. Univariate analysis showed that increased BMI at term, lower creatinine at term, longer duration from last dose of long- or intermediate-acting insulin, and discontinuation of an insulin infusion postpartum were associated with a shorter time to first requirement of insulin postpartum (P = 0.005, 0.026, 0.026, and <0.001, respectively). There was a correlation between higher doses of insulin commenced postpartum and number of out-of-range BGLs (r[36] = 0.358, P = 0.030) and hypoglycemia (r[36] = 0.434, P = 0.007). Almost 60% had at least one BGL <3.5 mmol/L between delivery and discharge. CONCLUSIONS: Changes in the pharmacodynamic profile of insulin may contribute to the transient insulin independence sometimes observed postpartum in type 1 diabetes. A dose of 50-60% of the prepregnancy insulin requirement resulted in the lowest rate of hypoglycemia and glucose excursions. These results require validation in a larger, prospective study.


Assuntos
Glicemia/metabolismo , Diabetes Mellitus Tipo 1/sangue , Hipoglicemia/tratamento farmacológico , Insulina/uso terapêutico , Período Periparto , Gravidez em Diabéticas/sangue , Adulto , Idoso , Austrália , Diabetes Mellitus Tipo 1/tratamento farmacológico , Feminino , Humanos , Gravidez , Gravidez em Diabéticas/tratamento farmacológico , Estudos Prospectivos , Estudos Retrospectivos
4.
Obstet Med ; 7(2): 52-9, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-27512424

RESUMO

Most women with type 1 diabetes mellitus (T1DM) have increased insulin requirements during pregnancy. However, a minority of women have a fall in insulin requirements. When this occurs in late gestation, it often provokes concern regarding possible compromise of the feto-placental unit. In some centres, this is considered as an indication for delivery, including premature delivery. There are, however, many other factors that affect insulin requirements in pregnancy in women with type 1 diabetes mellitus and the decline in insulin requirements may represent a variant of normal pregnancy. If there is no underlying pathological process, expedited delivery in these women is not warranted and confers increased risks to the newborn. We will explore the factors affecting insulin requirements in gestation in this review. We will also discuss some novel concepts regarding beta-cell function in pregnancy.

5.
Aust N Z J Obstet Gynaecol ; 52(1): 96-100, 2012 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22188308

RESUMO

Pregnancy in women with Cushing's syndrome (CS) is uncommon. It is associated with significant maternal and fetal complications. Pregnancy-induced Cushing's syndrome is exceptionally rare with fewer than ten cases reported in the world literature and none in Australia or New Zealand. We describe a woman with possible recurrent pregnancy-induced CS complicating five pregnancies over a 7-year period. We discuss the changes in the hypothalamic-pituitary-adrenal axis during normal pregnancy together with the diagnosis, aetiology and management of CS in pregnancy.


Assuntos
Síndrome de Cushing/etiologia , Inibidores Enzimáticos/uso terapêutico , Hidrocortisona/metabolismo , Sistema Hipotálamo-Hipofisário/fisiologia , Metirapona/uso terapêutico , Sistema Hipófise-Suprarrenal/fisiologia , Complicações na Gravidez/diagnóstico , Hormônio Adrenocorticotrópico/sangue , Adulto , Austrália , Síndrome de Cushing/diagnóstico , Síndrome de Cushing/terapia , Feminino , Humanos , Nova Zelândia , Gravidez/fisiologia , Complicações na Gravidez/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA